During the past decade, Meditek Ltda. conducted 4 clinical trials. In the 10-year time frame, 4 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 3 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Meditek Ltda." are "Chronic Obstructive Pulmonary Disease" (1 trials), "Early Breast Cancer" (1 trials), "HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer" (1 trials) and "Systemic Lupus Erythematosus" (1 trials). Many other conditions were trialed in "Meditek Ltda." in a lesser frequency.

Most popular intervention types in "Meditek Ltda." are "Drug" (4 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (2 trials), "Astegolimab" (1 trials), "Bevacizumab" (1 trials), "Capecitabine" (1 trials) and "Cenerimod 0.5 mg" (1 trials). Other intervention names were less common.

The vast majority of trials in "Meditek Ltda." are 4 trials for "All" genders.

Currently, there are NaN active trials in "Meditek Ltda.". undefined are not yet recruiting, 3 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in Meditek Ltda., undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Meditek Ltda., 0 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 1 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".